Exclusive Summary

• Targets a massive global pool of approximately 301 million anxiety patients, providing strong demand as a non-addictive, non-controlled anxiolytic alternative.
• Zero patent barriers (genericized since 2001) combined with ready-to-file dossiers allow distributors to achieve rapid registration and market penetration.
• Offers excellent clinical value with fewer side effects than benzodiazepines, widely recommended in international guidelines as an adjunct to SSRIs for Generalized Anxiety Disorder.
• Leverages China's highly integrated API-to-FDF supply chain to deliver exceptional cost advantages, ensuring high-profit margins for overseas distributors in public tenders and private markets.